Research Analysts’ Downgrades for June 29th (AMRX, BRSL, CHEF, CRM, CVS, EVMN, HBT, NGVT, NMG, TFC)

Research Analysts’ downgrades for Monday, June 29th:

Amneal Pharmaceuticals (NASDAQ:AMRX) was downgraded by analysts at Wall Street Zen from a strong-buy rating to a buy rating.

Brightstar Lottery (NYSE:BRSL) was downgraded by analysts at Argus from a buy rating to a hold rating.

Chefs’ Warehouse (NASDAQ:CHEF) was downgraded by analysts at Wall Street Zen from a buy rating to a hold rating.

Salesforce (NYSE:CRM) was downgraded by analysts at Phillip Securities from a buy rating to a neutral rating. They currently have $166.00 target price on the stock, down from their previous target price of $253.00.

CVS Health (NYSE:CVS) was downgraded by analysts at Wall Street Zen from a buy rating to a hold rating.

Evommune (NYSE:EVMN) was downgraded by analysts at William Blair from an outperform rating to a market perform rating.

HBT Financial (NASDAQ:HBT) was downgraded by analysts at Wall Street Zen from a buy rating to a hold rating.

Ingevity (NYSE:NGVT) was downgraded by analysts at Wall Street Zen from a strong-buy rating to a buy rating.

Nouveau Monde Graphite (NYSE:NMG) was downgraded by analysts at Wall Street Zen from a hold rating to a sell rating.

Truist Financial (NYSE:TFC) was downgraded by analysts at Wall Street Zen from a hold rating to a sell rating.

Ultra Clean (NASDAQ:UCTT) was downgraded by analysts at Wall Street Zen from a buy rating to a hold rating.

Receive News & Ratings for Amneal Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.